Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Recent advances in genitourinary tumors: A review focused on biology and systemic treatment.
González Del Alba A, Arranz JÁ, Puente J, Méndez-Vidal MJ, Gallardo E, Grande E, Pérez-Valderrama B, González-Billalabeitia E, Lázaro-Quintela M, Pinto Á, Lainez N, Piulats JM, Esteban E, Maroto Rey JP, García JA, Suárez C. González Del Alba A, et al. Crit Rev Oncol Hematol. 2017 May;113:171-190. doi: 10.1016/j.critrevonc.2017.03.010. Epub 2017 Mar 14. Crit Rev Oncol Hematol. 2017. PMID: 28427506 Review.
Weekly cabazitaxel plus prednisone is effective and less toxic for 'unfit' metastatic castration-resistant prostate cancer: Phase II Spanish Oncology Genitourinary Group (SOGUG) trial.
Climent MÁ, Pérez-Valderrama B, Mellado B, Fernández Parra EM, Fernández Calvo O, Ochoa de Olza M, Muinelo Romay L, Anido U, Domenech M, Hernando Polo S, Arranz Arija JÁ, Caballero C, Juan Fita MJ, Castellano D. Climent MÁ, et al. Eur J Cancer. 2017 Dec;87:30-37. doi: 10.1016/j.ejca.2017.09.028. Epub 2017 Nov 2. Eur J Cancer. 2017. PMID: 29102858 Clinical Trial.
SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017).
Cassinello J, Arranz JÁ, Piulats JM, Sánchez A, Pérez-Valderrama B, Mellado B, Climent MÁ, Olmos D, Carles J, Lázaro M. Cassinello J, et al. Clin Transl Oncol. 2018 Jan;20(1):57-68. doi: 10.1007/s12094-017-1783-2. Epub 2017 Nov 13. Clin Transl Oncol. 2018. PMID: 29134562 Free PMC article.
SNPs associated with activity and toxicity of cabazitaxel in patients with advanced urothelial cell carcinoma.
Duran I, Hagen C, Arranz JÁ, Apellaniz-Ruiz M, Pérez-Valderrama B, Sala N, Lainez N, García-Del Muro X, Noguerón E, Climent MÁ, Maroto P, Font A, García-Donas J, Gallardo E, López-Criado P, González Del Alba A, Sáez MI, Vázquez S, Luque R, Rodríguez-Antona C. Duran I, et al. Pharmacogenomics. 2016 Apr;17(5):463-71. doi: 10.2217/pgs.15.186. Epub 2016 Mar 29. Pharmacogenomics. 2016. PMID: 27020167 Clinical Trial.
Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma.
Puente J, Laínez N, Dueñas M, Méndez-Vidal MJ, Esteban E, Castellano D, Martinez-Fernández M, Basterretxea L, Juan-Fita MJ, Antón L, León L, Lambea J, Pérez-Valderrama B, Vázquez S, Suarez C, Del Muro XG, Gallardo E, Maroto JP, Samaniego ML, Suárez-Paniagua B, Sanz J, Paramio JM; SOGUG (Spanish Oncology Genitourinary Group). Puente J, et al. Oncotarget. 2017 May 2;8(18):30410-30421. doi: 10.18632/oncotarget.16494. Oncotarget. 2017. PMID: 28423742 Free PMC article.
38 results